Seagen has inked a deal to develop, manufacture and commercialize an experimental immuno-oncology agent from Lava Therapeutics, a biotech firm based mostly in Utrecht, Netherlands. Seagen pays Lava $50 million upfront to completely license Lava-1223, a “bispecific T cell engager” designed to direct sure T cells to tumors through the goal EGFR on most cancers cells. Seagen can even pay Lava as much as $650 million in future milestone funds and has the choice to completely negotiate rights to use Lava’s platform to 2 different tumor targets. The deal, introduced Monday, comes a month after talks over a possible acquisition of Bothell, Wash.-based Seagen by Merck reportedly stalled over the value.
See also Nearly 400 workers in Washington state will be laid off due to Amazon Care shutdown
Powered by Inline Related Posts